DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans cut its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 281,400 shares of the medical device company's stock after selling 32,702 shares during the period. Thrivent Financial for Lutherans owned approximately 0.07% of DexCom worth $21,885,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Whale Capital LLP boosted its position in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after acquiring an additional 113,000 shares during the last quarter. Motley Fool Asset Management LLC lifted its position in DexCom by 168.7% during the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock valued at $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC bought a new position in DexCom during the fourth quarter valued at $3,334,000. Congress Asset Management Co. grew its stake in shares of DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after buying an additional 222,548 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Remove Ads

DexCom Trading Down 2.3 %

DXCM traded down $1.77 during trading on Tuesday, hitting $73.55. 3,240,370 shares of the stock were exchanged, compared to its average volume of 3,915,036. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a market cap of $28.74 billion, a price-to-earnings ratio of 51.43, a P/E/G ratio of 2.30 and a beta of 1.28. The firm has a 50 day simple moving average of $83.24 and a 200 day simple moving average of $77.07. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Canaccord Genuity Group lifted their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday. Finally, Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.